Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for RHOA G17V mutated subtype

Ya Ting Hsu, Yu Chu Wang, Ruo Yu Chen, Liang Yi Hung, Sin Syue Li, Chi Chieh Yen, Tsai Yun Chen, L. Jeffrey Medeiros, Kung Chao Chang

Research output: Contribution to journalArticle

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) carries genetic mutations of TET2, RHOA, and IDH2, but the prognostic impact of these mutations is not widely investigated. Although one study shows no difference in overall survival between patients with or without RHOA G17V mutation, a poor performance status is associated with RHOA G17V-mutated AITL, which is an independent adverse factor. We retrospectively investigated the prognostic impact of RHOA G17V mutation in AITL patients. A total of 31 cases were enrolled (male-to-female, 2.1; mean age: 62.8 years). RHOA G17V mutation was analyzed by deep sequencing. We found that in contrast to RHOA-wild type, patients with RHOA G17V-mutated AITL more frequently had B symptoms (p =.035), stronger PD1 expression (p =.045), ≥3 TFH markers (p =.011), higher blood vessel density (p<.001), and poorer progression-free survival (p =.046). These results support a role for RHOA genetic testing in AITL patients as ROHA G17V mutation carries a worse prognosis, probably associated with B symptoms and stage IV disease.

Original languageEnglish
Pages (from-to)1108-1118
Number of pages11
JournalLeukemia and Lymphoma
Volume61
Issue number5
DOIs
Publication statusPublished - 2020 Apr 15

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for RHOA G17V mutated subtype'. Together they form a unique fingerprint.

  • Cite this